TABLE 2:

Baseline Characteristics for all eligible patients

Characteristic	Categories	Temozolomide + Irinotecan	Temozolomide + Irinotecan + Bevacizumab
Age at Enrollment	Median (Range|IQR1)	9 (1-21|6-13)	10 (0-18|7.5-13.5)
		Number (Percent)	Number (Percent)
Patient Sex	Male	33 (62.3)	36 (69.2)
	Female	20 (37.7)	16 (30.8)
Race	Asian	2 (3.8)	2 (3.8)
	Native Hawaiian or Pacific Islander	1 (1.9)	1 (1.9)
	Black or African American	8 (15.1)	6 (11.5)
	White	39 (73.6)	41 (78.8)
	Not Reported	3 (5.7)	2 (3.8)
Ethnicity	Hispanic or Latino	8 (15.1)	10 (19.2)
	Not Hispanic or Latino	44 (83.0)	42 (80.8)
	Not Reported	1 (1.9)	0 (0.0)
Extent of Disease at Enrollment	Measurable Disease	48 (90.6)	46 (88.5)
	Without Measurable Disease	5 (9.4)	6 (11.5)
Initial Diagnosis	Medulloblastoma	44 (83.0)	41 (78.8)
	Other Embryonal CNS Tumor	9 (17.0)	11 (21.2)
Received Radiation Therapy as a Component of Prior Therapy	Yes	44 (83.0)	45 (86.5)
	No	9 (17.0)	7 (13.5)